CG Oncology is a pre-commercial biotechnology company developing cretostimogene grenadenorepvec for non-muscle invasive bladder cancer, with a robust balance sheet of $1.0B equity but a rapidly shrinking cash position of $19.6M as of 2026Q2.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue is negligible at $1.2M in 2026Q2 with a negative gross margin of -2.4%, while R&D expenses of $54.7M drive operating losses of -$86.4M, reflecting a pre-commercial stage with escalating clinical costs.
CG Oncology initiated a rolling BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC, with full completion targeted for 2026, paving the way for potential FDA approval and launch by 2027.
The company's investment thesis centers on a pivotal Phase 3 trial for cretostimogene, with positive results significantly de-risking the stock and driving investor interest.
Bull Case scenarios project rapid adoption of cretostimogene, with potential FY2028 revenue reaching ~$700 million, significantly outperforming base and bear cases.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 6, 2026 | -$0.64+23.3% vs -$0.83 | $2M+192.9% vs $547,684 |
Q3 2026 Aug 6, 2026 | -$0.90-35.5% vs -$0.66 | $1M+220.7% vs $360,805 |
Q2 2026 May 8, 2026 | -$0.71-22.4% vs -$0.58 | $1M+139.1% vs $453,034 |
Q1 2026 Feb 27, 2026 | -$0.51+16.4% vs -$0.61 | $2M+412.9% vs $450,538 |
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.57 per share a year ago.
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.
CG Oncology is well-positioned to enter a de-risked NMIBC market with cretostimogene, offering a clean tolerability profile and randomized Phase 3 data. CGON's $1B+ cash position funds operations through 2029, with recent ATM activity signaling strong institutional interest rather than funding desperation. PIVOT-006 trial and BLA completion are imminent catalysts; positive results could unlock significant intermediate-risk NMIBC market potential.
CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the sale, the director directly owned 1,000 shares in the company,
Benchmark CGON against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CG Oncology Inc. (CGON)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $75.99 | $6.7B | -37.40 | 254.7% | -2928.43% | -18.69% | — | |
| $67.19 | $466.9M | 10.70 | 11.92% | 13.11% | 9.3% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $59.83 | $9.16B | 21.31 | 87.32% | 55.22% | 72.3% | — | |
| $17.63 | $1.08B | -11.14 | -5.55% | -428.74% | -10.68% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — |
CG Oncology Inc. (CGON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CG Oncology Inc. (CGON) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 8, 2026·SEC
May 26, 2026·SEC
Get notified when CGON posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CG Oncology Inc. (CGON) stock FAQ — growth, dividends, profitability & financials explained
CG Oncology Inc. (CGON) reported $6.2M in revenue over the trailing twelve months. Revenue was $4.0M in fiscal year 2025. That is 61% less than the $10.4M of fiscal year 2021.
CG Oncology Inc. (CGON) grew revenue by 183.6% over the trailing twelve months, compared with the twelve months before.
No. CG Oncology Inc. (CGON) reported a net loss of $180.6M over the trailing twelve months.
CG Oncology Inc. (CGON) had a return on equity (ROE) of -18.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
CG Oncology Inc. (CGON) had negative free cash flow of $189.2M over the trailing twelve months.
